Creative Medical Technology announces development of IPSCelz program

Creative Medical Technology Holdings has generated human induced pluripotent stem cells-derived Islet Cells that produce human insulin. The iPSC clinical line that generated these insulin producing Islet Cells is part of the Company’s iPSCelz program, which is validated by Greenstone Biosciences. The iPSC clinical line, which is currently utilized in a number of our FDA cleared clinical programs in the U.S., has also been utilized to derive validated mesenchymal cells and T-regulatory cells.